Stay updated on BLU-5937 Efficacy and Safety in Refractory Cough Clinical Trial
Sign up to get notified when there's something new on the BLU-5937 Efficacy and Safety in Refractory Cough Clinical Trial page.

Latest updates to the BLU-5937 Efficacy and Safety in Refractory Cough Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe BLU-5937 Phase 3 chronic cough study record is displayed, with its status marked completed and no longer recruiting. It includes study design, eligibility and treatment details, outcome measures, and participating locations.SummaryDifference100%

- Check15 days agoChange DetectedThe footer revision changes from v3.7.2 to v3.8.0 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check22 days agoChange DetectedA site-wide NIH banner announces a transition from using “Artificial Intelligence” to “Super Intelligence” in federal agency content.SummaryDifference1%

- Check29 days agoChange DetectedThe footer revision label changed from v3.7.1 to v3.7.2. The page continues to display a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check36 days agoChange DetectedThe footer revision label changed from v3.7.0 to v3.7.1 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check43 days agoChange DetectedThe ClinicalTrials.gov page now shows a 403 Forbidden message in place of the clinical study details.SummaryDifference17%

Stay in the know with updates to BLU-5937 Efficacy and Safety in Refractory Cough Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BLU-5937 Efficacy and Safety in Refractory Cough Clinical Trial page.